pegfilgrastim-cbqv

Actionable Insights Powered by AI

Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals for $558.4 Million

Coherus BioSciences, Udenyca, Intas Pharmaceuticals, pegfilgrastim-cbqv, immuno-oncology, pharmaceutical deal